Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics ( (TSE:BCT) ) has shared an announcement.
BriaCell Therapeutics announced the pricing of a public offering, expecting to raise $3.05 million through the sale of 762,500 common shares at $4.00 each. The proceeds will support working capital, general corporate purposes, and business advancement, potentially strengthening BriaCell’s operational and market position in the biotechnology industry.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies aimed at transforming cancer care. The company’s focus is on creating innovative treatments to improve patient outcomes in the oncology sector.
YTD Price Performance: -40.49%
Average Trading Volume: 5,412
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$21.31M
See more insights into BCT stock on TipRanks’ Stock Analysis page.